IceCure Medical FY2026 EPS Cut by Brookline Capital Markets

IceCure Medical Ltd. (NASDAQ:ICCM) – Analysts at Brookline Capital Markets dropped their FY2026 earnings per share (EPS) estimates for IceCure Medical in a research note issued to investors on Tuesday, March 17th. Brookline Capital Markets analyst K. Dolliver now forecasts that the company will post earnings per share of ($0.12) for the year, down from their prior estimate of ($0.06). The consensus estimate for IceCure Medical’s current full-year earnings is ($0.28) per share. Brookline Capital Markets also issued estimates for IceCure Medical’s FY2027 earnings at ($0.09) EPS, FY2028 earnings at ($0.04) EPS and FY2029 earnings at $0.08 EPS.

Several other equities research analysts also recently issued reports on ICCM. Wall Street Zen upgraded shares of IceCure Medical from a “sell” rating to a “hold” rating in a research report on Saturday, February 7th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of IceCure Medical in a research report on Thursday, January 22nd. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $2.64.

IceCure Medical Price Performance

ICCM stock opened at $0.63 on Friday. IceCure Medical has a fifty-two week low of $0.54 and a fifty-two week high of $1.40. The stock has a market capitalization of $45.95 million, a PE ratio of -2.62 and a beta of 0.29. The company has a 50 day moving average price of $0.62 and a 200 day moving average price of $0.74.

IceCure Medical (NASDAQ:ICCM) last posted its quarterly earnings data on Tuesday, March 17th. The company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.02). The company had revenue of $1.28 million during the quarter, compared to analyst estimates of $1.30 million. IceCure Medical had a negative net margin of 445.61% and a negative return on equity of 221.04%.

Institutional Investors Weigh In On IceCure Medical

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Virtu Financial LLC bought a new position in IceCure Medical during the 4th quarter worth $39,000. Concurrent Investment Advisors LLC acquired a new position in IceCure Medical in the 4th quarter valued at $48,000. Finally, Jane Street Group LLC bought a new stake in shares of IceCure Medical during the 4th quarter valued at $67,000. 0.62% of the stock is currently owned by institutional investors and hedge funds.

IceCure Medical News Summary

Here are the key news stories impacting IceCure Medical this week:

• Positive Sentiment: New peer‑reviewed PLOS One data highlighted by the company show its ProSense cryoablation is effective for treating breast fibroadenomas — a clinical win that supports product utility and potential commercial adoption if follow‑on studies/commercialization progress. IceCure Medical Highlights New PLOS One Data Showing ProSense Cryoablation Effective for Breast Fibroadenomas
• Positive Sentiment: Brookline Cap M’s long‑range model includes positive multi‑year estimates (FY2029/FY2030 projections) that suggest some analysts see upside over the longer term despite near‑term weakness — this can act as a tailwind if execution and commercial uptake match assumptions. ICCM on MarketBeat
• Neutral Sentiment: Q4 2025 earnings call transcript is available for review — useful for investors wanting management commentary on sales, clinical programs and cash burn after the recent quarterly miss. That context may influence positioning but is informational rather than a new catalyst. IceCure Medical Ltd (NASDAQ:ICCM) Q4 2025 earnings call transcript
• Negative Sentiment: Brookline Cap M issued a series of downward revisions to near‑term EPS estimates (cuts to FY2026, FY2027 and FY2028 and lowered quarterly 2026 EPS projections). Those model cuts lower near‑term profitability expectations and are the primary negative driver weighing on the stock today. ICCM on MarketBeat
• Negative Sentiment: Recent fundamental metrics (recent quarterly EPS miss, negative margins and high negative ROE) combined with the analyst downgrades increase downside risk until management can show consistent revenue growth or margin improvement. Investors should expect continued volatility around execution updates and clinical/commercial milestones. ICCM on MarketBeat

About IceCure Medical

IceCure Medical Ltd. (NASDAQ: ICCM) is a clinical-stage medical device company specializing in the development and commercialization of proprietary cryoablation systems for the treatment of tumors and other pathological tissues. The company’s core technology employs a unique liquid-nitrogen-based platform to deliver rapid cooling through fine-gauge cryoprobes, enabling precise and minimally invasive tissue ablation under imaging guidance. IceCure’s lead product, ProSense, is designed to offer a single-probe approach that can be deployed in an outpatient setting, reducing procedure time and patient recovery periods.

Originally founded in Israel, IceCure Medical obtained its first CE mark for the treatment of benign breast tumors and fibroadenomas in 2017.